[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:pre-mrna-processing-factor-31":3},{"name":4,"total":5,"recruiting":6,"trials":7},"PRE-mRNA-PROCESSING FACTOR 31",1,0,[8],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06852963","A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001",[12],"Phase 1\u002FPhase 2","ACTIVE_NOT_RECRUITING","2026-08-03T02:19:54.166214Z","2026-05-05T02:43:28.987926Z"]